Pricing Log in Create free account

GT Biopharma, Inc. (GTBP) vs NewcelX Ltd. (NCEL)

GT Biopharma, Inc. and NewcelX Ltd. are both Biotechnology companies. GT Biopharma, Inc. and NewcelX Ltd. are of similar size ($15.3M and $15.2M). Across the 10 metrics below, GT Biopharma, Inc. leads on 6 and NewcelX Ltd. on 4.

Valuation

Metric GTBP NCEL Biotechnology median
P/E n/m n/m 8.50
P/S 181.94 n/m 9.71
P/B 3.06 4.61 2.13
Price to free cash flow n/m n/m 20.82
EV/EBITDA n/m n/m 0.64
EV/Sales 542.75 n/m 9.21
Earnings yield (2,098.15%) (61.20%) (33.15%)
Free cash flow yield (130.63%) (17.60%) (25.50%)

Profitability

Metric GTBP NCEL Biotechnology median
Gross margin 41.67% 0.00% 65.16%
Operating margin 0.00% — 0.00%
Net margin 0.00% 0.00% 0.00%
Free cash flow margin 0.00% 0.00% 0.00%
Return on equity 102.03% 0.00% (56.36%)
Return on assets (176.27%) 0.00% (48.04%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric GTBP NCEL Biotechnology median
Revenue growth (TTM) (76.19%) — 6.02%
EPS growth (last fiscal year) 3.75% 11.18% 30.26%
Revenue growth, 5-year CAGR 19.67% — 9.41%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric GTBP NCEL Biotechnology median
Debt to equity 0.00 0.06 0.00
Current ratio 2.61 0.40 4.72
Net debt to EBITDA 0.56 0.74 0.96

Dividend

Metric GTBP NCEL Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric GTBP NCEL Biotechnology median
Market cap 15.17m 15.34m 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack